BCL2 and acute myeloid leukemia: BIK-associated mechanisms may be partially responsible for the observed complementary effect of the recently FDA-approved protocol for the treatment of AML in elderly patients, which implements a combination of Bcl-2 inhibitor Venetoclax and HMA [41].